Azura Ophthalmics
Sector: Healthcare & Life Sciences
About Azura Ophthalmics
Azura Ophthalmics Skip to content About Us Menu Toggle Who We Are Our Leadership Our Team Our Board of Directors Our Scientific Advisors Our Investors Science Menu Toggle Role of Keratolytics in Ophthalmology Publications Programs Menu Toggle Our Strategy R&D Pipeline Clinical Trials Patients News and Events Menu Toggle Press Releases Events Media Careers Main Menu About Us Menu Toggle Who We Are
Products
Azura
It is Azura’s belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms. Our additional areas of focus include the development of our novel New Chemical Entities which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action. It is Azura’s belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms. Our additional areas of focus include the development of our novel New Chemical Entities which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action